Investment Company News

20 Aug 2018

Augmentum makes three new investments

Augmentum makes three new investments – Augmentum Fintech has announced an aggregate of GBP 7 million of investment in three leading European fintech companies – Tide, Previse and DueDil. GBP3 million in Tide, an emerging leader in SME challenger banking, as part of an GBP8 million funding round alongside existing investors GBP2 million investment in Previse, the global […]

17 Aug 2018
Regional REIT adds eight offices to its portfolio

Regional REIT adds eight offices to its portfolio

Regional REIT adds eight offices to its portfolio Regional REIT (RGL) has announced that it has exchanged and completed on contracts to purchase eight assets for £31.4 million. (Update 24/08/2018) the acquisition was completed on 23rd August 2018. Regional diversification The portfolio is spread out from the Stockton-on-Tees in the North to High Wycombe in the South. […]

17 Aug 2018

BlackRock Emerging Europe’s liquidation plans announced

BlackRock Emerging Europe’s liquidation plans announced – on 14th June, the Board of BlackRock Emerging Europe (BEEP) announced that its tender offer had not secured enough money to make continuing running the company viable. Click here to read more on our coverage of that decision. The Board of BEEP have looked at the options and have come up with […]

16 Aug 2018

IBT adds to Celgene, reduces Neurocrine in July rejig

IBT adds to Celgene, reduces Neurocrine in July rejig International Biotechnology Trust (IBT) appears to have boosted its shareholding in Celgene – which has risen by one place and ~ two NAV  percentage points to become its top investee company, as part of a rejig of its largest investments in July. According to the trust’s latest […]

16 Aug 2018

Lazard World Trust Board responds to City of London letter

Lazard World Trust Board responds to City of London letter – On 15th August, we reported that City of London Investment Management (CLIG), who run the investment trust City of London (CTY), has written a letter to the Directors of Lazard World Trust Fund (WTR) explaining its intention to oppose renewing the WTR’s buyback authority at the EGM to be held on […]

16 Aug 2018

John Laing Environmental Assets acquires another anaerobic digestion plant

John Laing Environmental Assets acquires another anaerobic digestion plant – John Laing Environmental Assets (JLEN) has announced the acquisition of an anaerobic digestion (AD) asset, from Merlin Renewables Limited for a total consideration, including working capital, of c. £18.1 million. Location The Merlin AD plant is located in Hibaldstow, North Lincolnshire and was commissioned in September 2014. The […]

16 Aug 2018

Stafford Capital responds to Phaunos’ defence document

Stafford Capital responds to Phaunos’ defence document – on 14th August 2018, the Chairman of Phaunos Timber (PTF) sent a letter to Phaunos Shareholders, giving them an update on plans to wind up the company and to reject the cash offer made on 3rd July by Stafford Capital Partners. Click here to see a copy of the letter In […]

15 Aug 2018

City of London writes to shareholders of Lazard World Trust

City of London writes to shareholders of Lazard World Trust – City of London Investment Management (CLIG), who run the investment trust City of London (CTY), has written a letter to the Directors of Lazard World Trust Fund (WTR) explaining its intention to oppose renewing the WTR’s buyback authority at the EGM to be held on 30 August, 2018. CLIG comments that […]

14 Aug 2018

Regional REIT completes sale of Wardpark, Cumbernauld

Regional REIT completes sale of Wardpark, Cumbernauld – Regional REIT (RGL) has announced that it has exchanged and completed the sale of multi-let industrial estate Wardpark, Cumbernauld.  Uplift on disposal The sale price of £26.4m was 21.1% above the December 2017 year end valuation. Wardpark, Cumbernauld, which Regional REIT acquired in 2013, covers a total of 829,851 […]

14 Aug 2018

Alnylam receives expected FDA ok for Onpattro

Alnylam receives expected FDA ok for Onpattro Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) received its  first FDA approval late on Friday for Onpattro (patisiran) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. However, the FDA did not allow a broader label that included patients with cardiomyopathy (CM), leading to […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…